ReWalk Robotics Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReWalk Robotics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ReWalk Robotics stock.
View analyst ratings for ReWalk Robotics or view top-rated stocks.

Wall Street analysts have given ReWalk Robotics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ReWalk Robotics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ReWalk Robotics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ReWalk Robotics.

ReWalk Robotics Ltd. (NASDAQ:RWLK) posted its quarterly earnings results on Tuesday, May, 11th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.01. The medical device company earned $1.32 million during the quarter. ReWalk Robotics had a negative net margin of 246.47% and a negative trailing twelve-month return on equity of 40.84%.
View ReWalk Robotics' earnings history.

ReWalk Robotics' stock was trading at $0.6050 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RWLK stock has increased by 147.9% and is now trading at $1.50.
View which stocks have been most impacted by COVID-19.

1 equities research analysts have issued 12-month price targets for ReWalk Robotics' stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate ReWalk Robotics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 133.3% from the stock's current price.
View analysts' price targets for ReWalk Robotics or view top-rated stocks among Wall Street analysts.

Some companies that are related to ReWalk Robotics include Invacare (IVC), Conformis (CFMS), United Health Products (UEEC), Lakeland Industries (LAKE), Alpha Pro Tech (APT), Surgalign (SRGA), Milestone Scientific (MLSS), CollPlant Biotechnologies (CLGN), Predictive Oncology (POAI), Nutriband (NTRB), NanoVibronix (NAOV), Myomo (MYO), Allied Healthcare Products (AHPI), Wound Management Technologies (WNDM) and Bionik Laboratories (BNKL).
View all of RWLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ReWalk Robotics investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG) and Roper Technologies (ROP).

ReWalk Robotics trades on the NASDAQ under the ticker symbol "RWLK."

Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RWLK stock can currently be purchased for approximately $1.50.

ReWalk Robotics has a market capitalization of $69.18 million and generates $4.39 million in revenue each year. The medical device company earns $-12,980,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

ReWalk Robotics employs 49 workers across the globe.

The official website for ReWalk Robotics is www.rewalk.com.

ReWalk Robotics is headquartered at 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203.

ReWalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123 or via email at [email protected]